1 / 17

AIPLA Mid-Winter Institute January 31, 2013 Natalie Wright Curley, JD Managing Director,

Personalized Medicine/ Diagnostics/ Chemical-Complex Ecosystems Produce Various Strategies Connecting IP with Products and Services. AIPLA Mid-Winter Institute January 31, 2013 Natalie Wright Curley, JD Managing Director, Office of Technology Commercialization. MD ANDERSON BACKGROUND

maxine-ross
Download Presentation

AIPLA Mid-Winter Institute January 31, 2013 Natalie Wright Curley, JD Managing Director,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Personalized Medicine/ Diagnostics/ Chemical-Complex Ecosystems Produce Various Strategies Connecting IP with Products and Services AIPLA Mid-Winter Institute January 31, 2013 Natalie Wright Curley, JD Managing Director, Office of Technology Commercialization

  2. MD ANDERSON BACKGROUND Established in 1941 by the Texas State Legislature and matching funds from Monroe Dunaway Anderson. One of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971. One of 41 National Cancer Institute-designated comprehensive cancer centers . In 2011, MD Anderson marked its 70-year anniversary and welcomed Ronald DePinho, M.D., as the fourth full-time president in the institution's history. Ranked as the best hospital in the nation for cancer care 8 out of the past 10 years by US News and World Report. Currently employs more than 19,000 people, including 1,600 faculty.

  3. Our Mission To eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

  4. Patient Care • FY 2012 *115,000 patients seen, nearly 1/3 new patients

  5. MD Anderson Locations Centro Oncológico MD Anderson International España (Madrid, Spain) MD Anderson Cancer Center Main Campus, Houston, TX MD Anderson Radiation Treatment Center in Istanbul at American Hospital (Turkey) MD Anderson Radiation Treatment Center at Presbyterian Kaseman Hospital (Albuquerque, NM) Banner MD Anderson Cancer Center (Gilbert, AZ) MD Anderson Cancer Center-Orlando (FL)

  6. TEXAS • In addition to MD Anderson’s main campus in the Texas Medical Center in Houston, multiple regional care centers: • Regional Care Center in the Bay Area (Nassau Bay) • Regional Care Center in Katy • Regional Care Center in Sugar Land • Regional Care Center in The Woodlands • Two research campuses in Bastrop County, Texas

  7. Research funding • FY 2011

  8. Of MD Anderson’s total revenue of $3.7 billion in FY12, only 4.6% was general revenue appropriated by the State of Texas. Sources of Revenue (in millions)

  9. Office of Technology Commercialization • Obtain invention disclosures from faculty; • Evaluate for patentability and commercial potential; • Oversee patent drafting and prosecution; • Out license discoveries for commercial development and sale; • Create new companies to commercialize university technologies; • Goal: generate revenue to contribute back to mission!

  10. Diagnostics on the Scene! • Patient demand; • Shorter time to market (especially compared to those difficult therapeutic approvals!!!); • Better technologies at cheaper costs; • Money easy to get; • Patient samples available. • Personalized Medicine! As a result, we saw a surge in “diagnostic discoveries.”

  11. Invention Disclosures (average 134/year) Before 2010 After 2010

  12. Hmmm….Diagnostic “Market” Issues There is a need, BUT…. • Markers are changing and under debate.   • If new/better biomarkers are identified, how can these be validated and included on an existing panel? Cost? Regulatory approval? • Tests often stratified by disease type; diagnostic; prognostic; predictive…not a one size fits all market. • Regulatory uncertainty—not clear what the FDA will require. • Patentability issue…Supreme Court ruling on Prometheus has cast a cloud over the patentability of diagnostics in general; Myriad to be heard by SC. • Potential infringement of previously issued patents/FTO. • Reimbursement not certain. • Indicated course of treatment may still not be clear. • Funding is difficult.

  13. Diagnostic “Technology” Issues CURRENT PRACTICE Patient treated based on original biopsy CHALLENGE Patient outcome is determined by metastatic tumor Does the primary tumor represent metastatic or recurrent tumor? Are there subclones in the primary tumor? Are they selected by the metastatic process? Does it matter?

  14. Heterogeneity and Molecular Evolution Primary Metastasis Assay LossGainDiscordance PTEN 10% (5/46) 15% (8/46) 25% PIK3CA 8% (4/21) 8% (4/21) 16% marked change 8% (4/21) 12% (6/21) 20% ER (38) 7% (4/38) 0% (0/38) 7% PR 12% (7/38) 3% (2/38) 15% HER2 2% (1/12) 2% (1/12) 4% *n=51 tumors and 56 metastases Ana Gonzalez; FundaMeric; Kat Hale

  15. HETEROGENEITY: DO DIFFERENT SUBLCONES METASTASIZE TO DIFFERENT SITES Breast Cancer PIK3CA (Exon 9/20 only) 48% discordance between primary and metastasis Example Primary WT Metastasis #1 H1047R Metastasis #2 E542K Deep sequencing of primary tumor may identify mutations Jensen et al. 2011 E542K

  16. Functionality WHAT CLONE FREQUENCY MATTERS FOR PATIENT OUTCOMES????Drivers and passengers: Specific mutation mattersFunctional genomics program • How do we know which mutations are functional drivers and which ones are noise? (More of a problem as more genes are examined and we expand to whole exome sequencing.) • Current offerings only tell us which genes are mutated, not which ones are functional.

  17. Opportunities HOW CAN WE DEVELOP A MODEL THAT ADDRESSES THESE ISSUES????? Panels; Functional information; Better biopsy technologies; Improved certainty from regulatory and legal/PTO landscape; Reimbursement criteria/economics.

More Related